title: The CAIRP (CAndesartan for In-stent Restenosis Prevention) Trial--a multicenter study of AT1-receptor blocker therapy in coronary stenting.
abstract: Angiotensin II (Ang II) is implicated in the development of in-stent restenosis (ISR). Ang II- and AT1-receptor blockade could possibly reduce ISR. We enrolled 206 patients into a prospective double-blind, placebo-controlled, multicenter randomized trial of candesartan cilexitil 16 mg to test this notion. Mean lumen diameter (MLD) was the primary objective measured by quantitative coronary angiography and intravascular ultrasound. The Candesartan Group showed a trend towards a larger MLD at follow up without significant differences in the binary ISR rate. In vessels < 2.75 mm, we found a larger MLD in the treatment group after 6 months. This might indicate the potential benefit of AT1-receptor blocker therapy for certain subgroups when percutaneous coronary intervention is performed with bare-metal stent implantation.
authors.affiliation: Franz-Volhard-Klinik, Dept. for Molecular and Clinical Cardiology, HELIOS Klinikum Berlin, Charité, CBB, Wiltbergstrasse 50, 13125 Berlin, Germany.
authors.forename: Jochen
authors.initials: J
authors.lastname: Krämer
authors.forename: Rainer G
authors.initials: RG
authors.lastname: Ruf
authors.forename: Sibylle
authors.initials: S
authors.lastname: Schmidt
authors.forename: Christoph
authors.initials: C
authors.lastname: Axthelm
authors.forename: Ruth
authors.initials: R
authors.lastname: Strasser
authors.forename: Gerhard
authors.initials: G
authors.lastname: Janssen
authors.forename: Torsten
authors.initials: T
authors.lastname: Thieme
authors.forename: Angelika
authors.initials: A
authors.lastname: Kusch
authors.forename: Jürgen
authors.initials: J
authors.lastname: Waigand
authors.forename: Rainer
authors.initials: R
authors.lastname: Dietz
authors.forename: C Michael
authors.initials: CM
authors.lastname: Gross
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D019917:Blood Vessel Prosthesis Implantation; D003131:Combined Modality Therapy; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000188:drug therapy / Q000517:prevention & control* / Q000601:surgery; D004311:Double-Blind Method; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011446:Prospective Studies; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D010919:Placebos; D013777:Tetrazoles; C081643:candesartan